In 2016, the company was sold to Astellas Pharma and is now a subsidiary. XING Mitglieder mit ähnlichen Profilangaben. PitchBook is a financial technology company that provides data on the capital markets. Ganymed Pharmaceuticals AG is a biopharmaceutical company developing a new class of immunotherapeutic cancer drugs called Ideal Monoclonal Antibodies (IMABs). The company is building a pipeline of antibody therapeutics targeting solid cancers with medical need and large-market potential. Recognizing their global resources, I am … Co-founder of Ganymed Pharmaceuticals Biography She is an M.D. This feature is only available to our premium service subscribers. Sahin was behind the cooperation between Pfizer and BioNTech on … Türeci credits their rapid success in part to international collaboration, as BioNTech worked with Chinese firm Fosun Pharma and itself has staff from 60 countries.  She is internationally active as a lecturer. Then, in 2001, they founded Ganymed Pharmaceuticals… 12, 55131 Mainz.  Her mother is a Turkish biologist. Ist GANYMED Pharmaceuticals AG der richtige Arbeitgeber für Dich? Starting in 2000, Sahin and Türeci had together been leading a research group at University of Mainz. Frühere Anschriften: 1. München. In 2001, the couple launched the Ganymed Pharmaceuticals biopharmaceutical company to develop immunotherapeutic cancer drugs. In 2001 Şahin and his immunologist wife, Özlem Türeci, cofounded Ganymed Pharmaceuticals; Astellas Pharma acquired Ganymed in 2016 for $460 million. Er wurde von Zeus geliebt.  Ganymed and also BioNTech, which was founded later, are spin-offs of the Johannes Gutenberg University Mainz. He is a member of numerous scientific committees, in particular the international Association of Cancer Immunotherapy (CIMT), which he co-founded and chairs. Get the full list », You’re viewing 1 of 12 board members. Forschungsschwerpunkte: GANYMED Pharmaceuticals AG ist ein führendes biopharmazeutisches Unternehmen, das hoch tumorspezifische Antikörperwirkstoffe gegen neue Zielstrukturen zur gezielten Behandlung solider Tumore entwickelt.Das Unternehmen verfügt über eine der leistungsstärksten integrierten Komplettlösungen im Bereich der Antikörpertherapeutika, von der Identifizierung … HRB47318 MAINZ. Die japanische Astella Pharma Inc. übernimmt die in Mainz ansässige Ganymed Pharmaceuticel AG. Dr. Kumar has also served as …  The couple married In 2002; they have a daughter together. Get the full list », You’re viewing 5 of 15 investors. This ... Şahin was one of the founders of the biotechnology company BioNTech, based in Mainz, Germany, in 2008 and has been its CEO ever since.  This is a biopharmaceutical research institute that develops new diagnostics and drugs for the therapy of cancer and other diseases with high unmet medical needs.  From 2009 to 2018, she served as chair of the company's scientific advisory board. In 2001, the couple launched the Ganymed Pharmaceuticals biopharmaceutical company to develop immunotherapeutic cancer drugs. Corporate Name: Ganymed Pharmaceuticals AG (2) Location: Mainz, Germany (3) Representative: Özlem Türeci, CEO (4) Founded year: 2001 (5) Capital Stock: EUR 1,416,308 (as of end of May 2016) (6) Number of employees: 85 (7) Relationship with Astellas: There is no relationship between Astellas and Ganymed required to be disclosed Ganymed Pharmaceuticals AG is a leading biopharmaceutical company focusing on the development of a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs) for the treatment of solid cancers. Developer of antibody therapeutics for the treatment of solid cancers. Login. EUR in Ganymed investiert.  She and her husband decided over breakfast to apply the mRNA vaccine technology they had been researching for two decades to the emerging COVID-19 pandemic, which at the time was spreading in China. Developer of antibody therapeutics for the treatment of solid cancers. Managing Partner / Publisher. Köln. Neil Kumar, Ph.D., is a co-founder and has served as our Chief Executive Officer and a member of our board of directors since April 2015. From 2018 to April 2019, Prof. Huber served as a member of the supervisory board of TRON. Molekulare und Angewandte Biotechnologie. Tokyo and Mainz, October 28, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Ganymed Pharmaceuticals AG (CEO; Özlem Türeci, “Ganymed”), a biopharmaceutical company located in Mainz, Germany which focuses on the development of antibodies against cancer, announced today that Astellas and Ganymed’s shareholders have entered into an … Tokyo, December 21, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has completed the acquisition of Ganymed Pharmaceuticals AG (“Ganymed”), a biopharmaceutical company located in Mainz, Germany, and Ganymed has become a wholly owned subsidiary of Astellas as of CET December 20, 2016. September 1965 in İskenderun, Türkei) ist ein deutscher Mediziner. Roshini Beenukumar. , Born in Lastrup, Türeci is the daughter of a Turkish surgeon father from Istanbul, who worked at the Catholic hospital St. Elisabeth-Stift in Lastrup in the district of Cloppenburg. Abstract 2067. Özlem was the co-founder of Ganymed Pharmaceuticals AG, a clinical stage biotech company developing unique high-precision antibodies against various solid cancers that was sold to Astellas Pharma Inc. for EUR 422 million in 2016. GANYMED Pharmaceuticals AG is a biotechnology company based out of 12Freiligrathstraße, Mainz, Rhineland-Palatinate, Germany. Auf LinkedIn können Sie sich das vollständige Profil ansehen und mehr über die Kontakte von Özlem Türeci und Jobs bei ähnlichen Unternehmen erfahren. Als erstes europäisches Unternehmen hat BioNTech in Kooperation mit Pfizer ein mRNA-basiertes COVID-19- Vakzin entwickelt und Anfang …  She was a habilitation and Heisenberg fellow of the German Research Foundation. Türeci and her family continue to live in a modest apartment. Prof. Huber earned his MD at the University of Innsbruck. … Beispiel-Dokument.  Before studying medicine, she hoped to become a nun.. Company profile page for Ganymed Pharmaceuticals AG including stock price, company news, press releases, executives, board members, and contact information Its majority shareholder is ATS Beteiligungsverwaltung GmbH. She is internationally active as a lecturer. Together with her husband Ugur Sahin and her mentor Christoph Huber, they developed the concept of a "translational institute", which was realized in 2001 with the foundation of TRON. Ganymed Pharmaceuticals GmbH, Mainz, Germany, District Court of Mainz HRB 47318: Earnings, Public funding, Revenue, Employees, Network, Financial information IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. Özlem is co-founder of TRON and was founder and Chief Executive Officer of Ganymed Pharmaceuticals AG, now a subsidiary of Astellas Pharma Inc. She was also central in the founding of BioNTech SE, where she now serves as chairperson of the scientific and clinical advisory board and Chief Medical Officer.  Türeci and her spouse, Uğur Şahin, became the first Turkish Germans among Germany's top 100 wealthiest people list in 2020. Background. BioNTech. Ihr derzeitiger Status ist "eingetragen". … Mainz, Germany. Türeci met her future husband, Uğur Şahin, while he was working at Saarland University Hospital in Homburg, where she was completing her final year of studies. Şahin co-founded the company Ganymed Pharmaceuticals in 2001 with his wife, Özlem Türeci. Die Ganymed Brasserie befindet sich direkt an der Spree mit einem fantastischen Blick zum Fernsehturm, eingebettet zwischen Museumsinsel und Brandenburger Tor. Ganymed, auch Ganymedes (altgriechisch Γανυμήδης Ganymếdês „der Glanzfrohe“; lateinisch Catamitus), ist in der griechischen Mythologie ein Sohn des trojanischen Königs Tros und der Kallirrhoë, Bruder des Assarakos und des Ilos, und der „Schönste aller Sterblichen“. They sold the firm in 2016 for €422 million ($502 million). Die Firma wurde vor vier Jahren für mehr als 400 Millionen Euro an ein japanisches Pharmaunternehmen verkauft. Freiligrathstr. Türeci is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Resarch (AACR), the German Society of Immunology [de], and the German Society of Hematology and Oncology [de]. BioNTech Co-Founder als Speaker. Personalize which data points you want to see and create visualizations instantly. Ganymed Pharmaceuticals AG An der Goldgrube 12 55131 Mainz. Get the full list », Co-Founder, Chief Executive Officer & Chief Medical Officer, Co-Founder, Chief Operating Officer & Chief Financial Officer, Co-Founder, Vice Chairman and Deputy Chairman Supervisory Board. Sehen Sie sich das Profil von Özlem Türeci im größten Business-Netzwerk der Welt an. Dr Türeci was chief executive and Dr Sahin was in charge of research. Ob kurz-, längerfristig oder dauerhaft, die GANYMED® Gehhilfen unterstützen in jeder Situation. Firmenbeschreibung Ganymed Pharmaceuticals GmbH Ganymed Pharmaceuticals GmbH ist eine in Deutschland als Gesellschaft mit beschränkter Haftung registrierte Firma mit der Register-Nr. Die Firma wurde 22.03.2017 registriert. Current Position. Sehen Sie sich das Profil von Özlem Türeci im größten Business-Netzwerk der Welt an. Resources. Duis aute irure dolor in reprehenderit in volupta, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Die 2001 gegründete Ganymed Pharmaceuticals entwickelt immuntherapeutische Krebsmedikamente. Das biopharmazeutische Unternehmen, 2001 als Spin-off der Universitäten Mainz und Zürich gegründet, entwickelt Antikörper zur gezielten Krebstherapie (Ideal Monoclonal Antibodies - IMABs). 1 Ganymed Pharmaceuticals, AG, 55131 - Mainz/DE; 2 Ganymed Pharmaceuticals, AG, Mainz/DE; 3 Translational Oncology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz/DE More. Other investors include Future Capital AG, MIG Fonds, FCPB Gany GmbH, and private individuals. Dadurch zerstören sie die Tumorzellen, nicht aber das gesunde Gewebe. Recognizing their global resources, I am also confident that Astellas will be able to turn innovative science and promising clinical results into near-term value for patients.”. In the 90s, before we started Ganymed, our research team was led by Ugur Sahin – the CEO of BioNTech, and also a co-founder of Ganymed – and me. They sold the firm in 2016 for €422 million ($502 million). Rheda-Wiedenbrück. GANYMED Pharmaceuticals AG | 422 Follower auf LinkedIn GANYMED Pharmaceuticals AG is a biotechnology company based out of 12Freiligrathstraße, Mainz, Rhineland-Palatinate, Germany. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently … Özlem Türeci (Turkish pronunciation: [ˈœzlæm ˈtyredʒi]; born 6 March 1967) is a German physician, scientist and entrepreneur. They cycle to work and do not own a car. Mit ihrer ersten Firma "Ganymed" konnten Türeci und Sahin Sponsorengeld einwerben. R. Mitnacht-Kraus: Employee of Ganymed Pharmaceuticals AG, a company of Astellas Pharma, Inc. That firm, Ganymed Pharmaceuticals, was sold to Astellas Pharmaceuticals in 2016 for $460 million (plus an additional $940 million if certain milestones were … All rights reserved. Ganymed Pharmaceuticals AG is a biopharmaceutical company developing a new class of immunotherapeutic cancer drugs called Ideal Monoclonal Antibodies (IMABs).